Ligand Pharmaceuticals, Inc. (LGNDZ)
Oxford Ledge is still expanding full research coverage of LGNDZ. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Ligand deploys capital into diversified royalty streams from biopharmaceutical products while maintaining minimal operational infrastructure.
SEC filings
- 8-K Entry into material agreement; Financial statements and exhibits 2026-05-18
- 10-Q Quarterly financial report (unaudited) 2026-05-08
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-07
- 8-K Termination of material agreement 2026-04-30
- 8-K Entry into material agreement; Other material event 2026-04-27
Source: SEC EDGAR.
- Open LGNDZ in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.